FDA Approves Lipfendra (enlicitide): The First Daily Pill to Target PCSK9 for Stubbornly High Cholesterol

Exciting news for patients managing cardiovascular health: the FDA has approved Lipfendra (enlicitide), a groundbreaking 20-mg once-daily tablet designed to lower low-density lipoprotein cholesterol (LDL-C)—commonly known as "bad" cholesterol.

This is a massive shift in lipid management. For years, targeting the PCSK9 protein required self-administered injections. Lipfendra brings that same powerful mechanism into a convenient, daily pill.

How Lipfendra Works: Blocking PCSK9 Orally

Your liver uses specialized receptors to pull LDL ("bad") cholesterol out of your bloodstream. A naturally occurring protein called PCSK9 binds to these receptors and destroys them, leaving more cholesterol circulating in your blood.

By blocking—or inhibiting—PCSK9, Lipfendra allows your liver to keep more of those receptors active. The result? Your body becomes much more efficient at clearing bad cholesterol.

What makes Lipfendra unique is its macrocyclic peptide technology. Peptides are usually broken down rapidly by stomach acids, which is why previous PCSK9 inhibitors had to be injected. Lipfendra's unique structure allows it to survive the digestive tract and do its work directly as a pill.

What the Clinical Trials Showed

The FDA approval was backed by two massive Phase 3 clinical trials under the CORALreef program:

• CORALreef Lipids: In patients with high cholesterol and a high risk of cardiovascular events (already on stable statin therapy), Lipfendra demonstrated a 56% placebo-adjusted reduction in LDL-C at 24 weeks.

• CORALreef HeFH: In patients with Heterozygous Familial Hypercholesterolemia (an inherited, genetic form of aggressively high cholesterol), Lipfendra achieved a 59% placebo-adjusted reduction in LDL-C.
  

In addition to driving down LDL-C, trials showed significant reductions in other harmful markers, including a 54% reduction in non-HDL cholesterol and a 50% reduction in apolipoprotein B (ApoB).

Key Patient Guidelines

Taking Lipfendra correctly is crucial to ensuring your body absorbs the peptide medication properly.

• Morning Routine: Take one tablet daily in the morning on an empty stomach.

• Fluid Limits: Swallow the pill whole with only water, black coffee, or plain tea.

• The 30-Minute Rule: You must wait at least 30 minutes after taking Lipfendra before eating food or drinking anything else.

• Storage: Keep the tablets in their original bottle. The lid contains a special moisture-absorbing packet (desiccant) that must remain inside to protect the pills.
  

Side Effects & Safety

Overall, Lipfendra's safety profile in the general hypercholesterolemia group was comparable to a placebo. For patients with the genetic condition HeFH, the most common side effects reported at a slightly higher rate than placebo were:

• Dizziness (9% vs. 4% on placebo)

• Diarrhea (7% vs. 2% on placebo)
  

Note: While Lipfendra is highly effective at lowering LDL-C, long-term cardiovascular outcomes trials are still ongoing to formally establish its effect on stroke and heart attack risk.

Cost and Availability

Lipfendra is expected to be available in pharmacies within a few weeks.

• List Price: Set at $315 per month ($10.50 per day) before insurance.

• Affordability: This is up to 50% lower than the list price of many injectable PCSK9 options. The manufacturer plans to offer patient co-pay cards, and it will also be available through the TrumpRx direct-to-consumer channel.

The FDA's approval of Lipfendra (enlicitide) establishes it as the first oral PCSK9 inhibitor.

Clinical eligibility centers on adults who need significant LDL-C reduction but want or need an alternative to the traditional injectable PCSK9 inhibitors.

FDA-Approved Indications

Lipfendra is approved as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in:

• Adults with Hypercholesterolemia (Primary High Cholesterol): This includes individuals with elevated LDL-C who have a history of, or are at high risk for, a major atherosclerotic cardiovascular disease (ASCVD) event.

• Adults with Heterozygous Familial Hypercholesterolemia (HeFH): Patients with this specific inherited, genetic form of severely elevated cholesterol.
  

The Clinical Profile: Who is the Ideal Candidate?

While the official label is broad, the phase 3 clinical trial data (CORALreef Lipids and CORALreef HeFH) paint a clear picture of the specific patient profile that benefits most:

Metric / Scenario	Qualifying Patient Profile
Current Therapy	Already taking maximally tolerated statin therapy (with or without other lipid-lowering therapies like ezetimibe) but still failing to hit their target LDL-C.
Statin Intolerance	Patients who cannot tolerate therapeutic doses of statins and require robust non-statin therapy.
Expected Reduction	Those needing a dramatic drop in "bad" cholesterol—trials showed an average 56% to 59% reduction in LDL-C at 24 weeks.
Preference	Patients who qualify for a PCSK9 inhibitor but actively prefer a once-daily oral pill over bi-weekly or monthly subcutaneous injections.

Note on Outcomes: The current approval is based on its profound lipid-lowering efficacy. While traditional monoclonal antibody PCSK9 inhibitors are proven to lower cardiovascular events, the formal cardiovascular outcomes trial for enlicitide (CORALreef Outcomes) is still ongoing to definitively prove its impact on morbidity and mortality.

About Woodside Internal Medicine

Woodside Internal Medicine is a direct primary care practice dedicated to highly personalized, comprehensive preventative health. Located at the intersection of 96th and Meridian Street, we work closely with our patients to navigate the latest advancements in cardiovascular medicine, ensuring you have access to the safest and most effective treatments available. Contact our office today to schedule an introductory meet-and-greet.

Disclaimer: This information is for educational and informational purposes only and does not constitute medical advice. Talk to your healthcare provider to discuss your specific cholesterol management goals and to see if a PCSK9 inhibitor is appropriate for your treatment plan.